Dr. Jeff O’Callaghan

Our Retina International World Congress (RIWC24) takes place from the 5th – 8th June 2024 in the Dublin Royal Convention Centre, in the heart of Dublin city centre.

Our Scientific Committee has been working relentlessly to secure an impressive lineup of outstanding speakers to shed light on this research area so as part of our Meet the Speaker series, we are delighted to announce one more distinguished speaker.

Dr. O’Callaghan is a postdoctoral research fellow in Professor Matthew Campbell’s lab at Trinity College Dublin (TCD) as well as co-founder and senior scientist at Exhaura, an ocular gene therapy company based in Ireland focused on developing new technologies to bring new gene medicines to patients. 

We are delighted to have Dr. Jeffrey O’Callaghan with us at the Retina International World Congress talking on Friday, June 7, 3:40 PM – 4:00 PM about ‘The inner retina in age-related macular degeneration (AMD)’.

Image description: Headshot of Dr. Jeff O’Callaghan on a blue background image. Text: Retina International World Congress. Dublin Royal Convention Centre, Dublin, Ireland. RIWC24. DUBLIN: Targeting the Cure. JUNE 5-8, 2024. DR. JEFF O’CALLAGHAN, Postdoctoral research fellow, Prof. Matt Campbell lab, TCD, Co-founder and senior scientist, Exhaura company. At the bottom of the image, there are the Fighting Blindness and Retina International logos.

Dr. O’Callaghan is a postdoctoral research fellow in Professor Matthew Campbell’s lab at Trinity College Dublin (TCD) and specialises in designing and translating gene therapy-based approaches to ocular conditions. As part of the neovascular genetics laboratory in TCD, his research focuses on molecular biology methods to explore potential new targets in inherited retinal disorders, and then rapidly de-risk and translate these targets using the various mouse, primate and human donor tissue models available to the lab.

Dr O’Callaghan is a co-founder and senior scientist at Exhaura, an ocular gene therapy company based in Ireland focused on developing new technologies to bring new gene medicines to patients. As part of the Exhaura team, Dr O’Callaghan has extensive experience in pre-clinical and CMC target development. Exhaura’s primary product targeting the anterior segment holds great promise for glaucoma patients.

Dr O’Callaghan’s current research focus involves investigating the retinal microvasculature to discover new insights into the pathogenesis of retinal disorders. He has developed a software, FOVAS, to assess retinal images to determine the state of vascular integrity, disease progression and treatment efficacy to ultimately improve the quality of patient care. This software has demonstrated new findings in AMD patients, which may lead to novel target development.

Stay tuned for more updates as we draw closer to this incredible gathering of the latest scientific research and innovation, set to take place in June 2024!

For registrations please click here.